医药生物行业周报：重庆脑机接口获突破性进展，建立癫痫治疗新范式-20260109

Investment Rating - The report suggests a positive outlook for the invasive brain-computer interface (BCI) clinical field, indicating a broad application of the technology [5]. Core Insights - The invasive BCI technology has made significant clinical advancements, transitioning from laboratory research to practical applications, particularly in the treatment of drug-resistant epilepsy [4]. - A study conducted by a collaborative team has successfully decoded and personalized interventions for brain network activities in patients with drug-resistant epilepsy, marking a new paradigm in treatment [4]. - The research identified a specific high-frequency oscillation (fast ripple, FR) as a neural biomarker for the severity of epilepsy, allowing for targeted interventions that significantly reduce seizure frequency [4]. - Key nodes in the brain's FR network were found to be stable and safer for stimulation, with 87.5% of patients experiencing a reduction in seizure frequency by over 50% after targeted stimulation [4]. - The new approach shifts the treatment paradigm from localized resection to personalized modulation of abnormal brain networks, enhancing clinical application potential [4]. Summary by Sections Clinical Advancements - The report highlights the establishment of a specialized alliance for neuro-regulation and BCI technology in Chongqing, aimed at improving precision diagnosis and treatment for epilepsy and other neurological disorders [4]. Market Opportunities - The report recommends focusing on companies such as Innovation Medical, Aipeng Medical, and Sanbo Brain Science, which are positioned to benefit from advancements in the invasive BCI sector [5].